Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial.
Bonaca MP, Catarig AM, Houlind K, Ludvik B, Nordanstig J, Ramesh CK, Rasouli N, Sourij H, Videmark A, Verma S; STRIDE Trial Investigators.
Lancet. 2025 May 3;405(10489):1580-1593. doi: 10.1016/S0140-6736(25)00509-4. Epub 2025 Mar 29.
Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses.
Nanayakkara N, Curtis AJ, Heritier S, Gadowski AM, Pavkov ME, Kenealy T, Owens DR, Thomas RL, Song S, Wong J, Chan JC, Luk AO, Penno G, Ji L, Mohan V, Amutha A, Romero-Aroca P, Gasevic D, Magliano DJ, Teede HJ, Chalmers J, Zoungas S.
Diabetologia. 2021 Feb;64(2):275-287. doi: 10.1007/s00125-020-05319-w. Epub 2020 Dec 14.
Preventing foot ulcers in patients with diabetes.
Singh N, Armstrong DG, Lipsky BA.
JAMA. 2005 Jan 12;293(2):217-28. doi: 10.1001/jama.293.2.217.
Risk factors for peripheral artery disease and diabetic peripheral neuropathy among patients with type 2 diabetes.
Chen T, Xiao S, Chen Z, Yang Y, Yang B, Liu N.
Diabetes Res Clin Pract. 2024 Jan;207:111079. doi: 10.1016/j.diabres.2023.111079. Epub 2023 Dec 26.
Limb and cardiovascular event risk in type 1 and 2 diabetic patients with peripheral artery disease.
Sykora D, Firth C, Girardo M, Tseng A, Wennberg P, Liedl D, Shamoun F.
Vasa. 2023 Sep;52(5):310-316. doi: 10.1024/0301-1526/a001086. Epub 2023 Jul 31.
Association between plasma omentin-1 levels in type 2 diabetic patients and peripheral artery disease.
Biscetti F, Nardella E, Bonadia N, Angelini F, Pitocco D, Santoliquido A, Filipponi M, Landolfi R, Flex A.
Cardiovasc Diabetol. 2019 Jun 5;18(1):74. doi: 10.1186/s12933-019-0880-7.
Improved prognosis in type 1 diabetic patients with nephropathy: a prospective follow-up study.
Astrup AS, Tarnow L, Rossing P, Pietraszek L, Riis Hansen P, Parving HH.
Kidney Int. 2005 Sep;68(3):1250-7. doi: 10.1111/j.1523-1755.2005.00521.x.
Fenofibrate to prevent amputation and reduce vascular complications in patients with diabetes: FENO-PREVENT.
Ku EJ, Kim B, Han K, Lee SH, Kwon HS.
Cardiovasc Diabetol. 2024 Sep 3;23(1):329. doi: 10.1186/s12933-024-02422-9.
Association of Cardiovascular Autonomic Dysfunction With Peripheral Arterial Stiffness in Patients With Type 1 Diabetes.
Nattero-Chávez L, Redondo López S, Alonso Díaz S, Garnica Ureña M, Fernández-Durán E, Escobar-Morreale HF, Luque-Ramírez M.
J Clin Endocrinol Metab. 2019 Jul 1;104(7):2675-2684. doi: 10.1210/jc.2018-02729.
Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease.
Verma S, Al-Omran M, Leiter LA, Mazer CD, Rasmussen S, Saevereid HA, Sejersten Ripa M, Bonaca MP.
Diabetes Obes Metab. 2022 Jul;24(7):1288-1299. doi: 10.1111/dom.14700. Epub 2022 Apr 11.
